Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- May 5, 2022 Apellis Pharmaceuticals to Present at the Bank of America Securities 2022 Healthcare Conference
- May 4, 2022 Apellis Pharmaceuticals Reports First Quarter 2022 Financial Results
- May 3, 2022 Apellis Announces Dr. Peter Hillmen, Renowned Hematologist and PNH Expert, to Join Company
- May 2, 2022 Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
- April 26, 2022 Apellis Pharmaceuticals to Host Conference Call on May 4, 2022 to Discuss First Quarter 2022 Financial Results
- April 21, 2022 Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)
- April 4, 2022 Apellis Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
- March 28, 2022 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
- March 24, 2022 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- March 23, 2022 Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Displaying 121 - 130 of 303